Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05793151 · ClinicalTrials.gov registry record · NA

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

A NA study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Medical University of South Carolina.

Recruiting
Registry status
NA
Development phase
532
Enrollment target
4
Study locations

NCT05793151: Recruiting NA study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Medical University of South Carolina.

NCT05793151 is a NA study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 532 participants, above the 259-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (105% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05793151, a NA study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
NA
Development phase
532 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: 1. Does ENDURE improve initiation of timely PORT relative to treatment as usual? 2. What are the mechanisms through which ENDURE improves timeliness to treatment? 3. What are the barriers and facilitators to the implementation of ENDURE into routine clinical care?

Primary Outcome

The initiation of PORT \> 6 weeks (42 days) following definitive surgery for HNSCC.

Interventions

  • BEHAVIORAL ENDURE

Study Locations (4)

Missouri

  • Washington University in St. Louis - St Louis

North Carolina

  • Duke University Medical Center - Durham

South Carolina

  • Medical University of South Carolina - Charleston

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 532 participants
Start Date 2023-10-30
Est. Completion 2028-03-30
Phase NA

What NCT05793151 shows while recruiting

NCT05793151 is an interventional study that assigns participants to a tested intervention. The registered 532 participants enrollment target is mid-sized for trials with a published cap, above the 259-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (105% higher).

The record links to 5 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which ENDURE is the first listed.

NCT05793151 reports a single indexed study location in Missouri, North Carolina, South Carolina.

Frequently Asked Questions

What is clinical trial NCT05793151 about?

NCT05793151 is a clinical study titled "Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy". The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial ...

What is the current status of trial NCT05793151?

This trial is currently recruiting. It is a NA study. The enrollment target is 532 participants. The study started on 2023-10-30. Estimated completion is 2028-03-30.

What conditions does trial NCT05793151 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer.

What interventions are being tested in trial NCT05793151?

The interventions under investigation include: ENDURE (BEHAVIORAL).

Who is sponsoring clinical trial NCT05793151?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05793151 being conducted?

This trial has 4 study locations across Missouri, North Carolina, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05793151's enrollment target sits among peer trials

532 21st of 250 higher than 230 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06378866 · 532 participants · Phase 2

    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

  • NCT07219173 · 531 participants · Phase 2

    A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05793151, the US trial registry maintained by the National Library of Medicine. NCT05793151 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.